Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn-Strides has received the FDA approval of an abbreviated new drug application for tobramycin injection USP, 80mg/2mL and 1.2grams/30mL.
Subscribe to our email newsletter
Tobramycin injection is an antibiotic and is indicated for the use in treating or preventing infections that are proven or strongly suspected to be caused by susceptible bacteria.
Arthur Przybyl, president and CEO of Akorn and member manager of Akorn-Strides, said: “We are excited to announce this product approval for tobramycin injection.”